RPG Life Sciences Q1 FY27 Standalone Net Profit Rs. 3,057 Lakhs
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 28 Jul 2026, 07:53 PM IST · BSE ID: 042ff26b-60bb-4a56-832a-829be6371842
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has officially released its financial performance report for the last quarter.
🤖 AI Summary
- RPG Life Sciences Board approved unaudited standalone and consolidated financial results for Q1 FY27.
- Standalone Revenue from Operations was Rs. 19,569 Lakhs for the quarter ended June 30, 2026.
- Standalone Profit for the period reached Rs. 3,057 Lakhs for the quarter ended June 30, 2026.
- Consolidated Revenue from Operations was Rs. 19,569 Lakhs for the quarter ended June 30, 2026.
- Consolidated Profit for the period was Rs. 3,050 Lakhs for the quarter ended June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q1 FY27)
19,569 Rs. in Lakhs
15.85%
Standalone Profit for the period (Q1 FY27)
3,057 Rs. in Lakhs
16.20%
Consolidated Revenue from Operations (Q1 FY27)
19,569 Rs. in Lakhs
15.85%
Consolidated Profit for the period (Q1 FY27)
3,050 Rs. in Lakhs
16.09%
Standalone Basic EPS (Q1 FY27)
18.49 Rs.
16.29%
🏢 How This Affects the Company
The consistent revenue from operations at Rs. 19,569 Lakhs (standalone and consolidated) indicates stable core business activity for the quarter.
Standalone Profit for the period increased to Rs. 3,057 Lakhs from Rs. 2,629 Lakhs in the prior comparable period, reflecting improved earnings.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as reported by the unaudited standalone and consolidated results for Q1 FY27.
🔍
Management Signal
The management's approval of the unaudited results and inclusion of Limited Review Reports signals adherence to financial disclosure regulations.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check revenue and profit continuity.
Updates on API division transfer to RPG Active Pharma Limited.
Any further disclosures regarding New Labour Codes impact.
LOW RISK
The filing presents routine quarterly financial results with positive growth.
💡 Investor Takeaway
RPG Life Sciences reported Q1 FY27 standalone Revenue from Operations of Rs. 19,569 Lakhs, up 15.85% from Rs. 16,892 Lakhs in Q1 FY26. Standalone Profit for the period was Rs. 3,057 Lakhs, an increase of 16.20% from Rs. 2,629 Lakhs in Q1 FY26.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Revenue from Operations for Q1 FY27 increased to Rs. 19,569 Lakhs, up from Rs. 16,892 Lakhs in Q1 FY26.
- Standalone Profit for the period in Q1 FY27 grew to Rs. 3,057 Lakhs, compared to Rs. 2,629 Lakhs in Q1 FY26.
⚠️ Concerns
- Standalone Other Income decreased to Rs. 416 Lakhs in Q1 FY27 from Rs. 523 Lakhs in Q1 FY26.
- Consolidated Other Income decreased to Rs. 470 Lakhs in Q1 FY27 from Rs. 523 Lakhs in Q1 FY26.
❓ Frequently Asked Questions
What was RPG Life Sciences' standalone net profit for the quarter ended June 30, 2026?
RPG Life Sciences' standalone Profit for the period was Rs. 3,057 Lakhs for the quarter ended June 30, 2026.
What was RPG Life Sciences' consolidated revenue from operations for Q1 FY27?
RPG Life Sciences' consolidated Revenue from Operations was Rs. 19,569 Lakhs for the quarter ended June 30, 2026.
How did RPG Life Sciences' standalone basic EPS compare in Q1 FY27 to Q1 FY26?
Standalone Basic Earnings per Share (EPS) for Q1 FY27 was Rs. 18.49, up from Rs. 15.90 in Q1 FY26.
What was RPG Life Sciences' standalone total income for the quarter ended June 30, 2026?
RPG Life Sciences' standalone Total Income was Rs. 19,985 Lakhs for the quarter ended June 30, 2026.
What exceptional items were noted in RPG Life Sciences' financial results?
No exceptional items were reported for the quarter ended June 30, 2026. Exceptional items in prior periods included insurance claims, new labour codes impact, and impairment of intangible assets.
Questions based on this BSE filing only. For information purposes.